Treatment of chemotherapy-associated cardiomyopathy
The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dy...
Gespeichert in:
| Veröffentlicht in: | Current opinion in cardiology Jg. 34; H. 3; S. 296 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.05.2019
|
| Schlagworte: | |
| ISSN: | 1531-7080, 1531-7080 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival.
Recent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD. However, this is largely based on data extrapolated from the general heart failure population (including patients without cancers) and is not based on strong evidence. There is now emerging evidence for the prevention and treatment of heart failure related to certain established chemotherapeutic drugs, whereas there is lack of trials for specific cardioprotective strategies to reduce cardiotoxicity of newer targeted cancer therapies.
In this article, we discuss the most recent literature for the management of asymptomatic left ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use of goal-directed medical therapies as well as discuss the role for advanced heart failure treatment in this population. |
|---|---|
| AbstractList | The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival.PURPOSE OF REVIEWThe number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival.Recent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD. However, this is largely based on data extrapolated from the general heart failure population (including patients without cancers) and is not based on strong evidence. There is now emerging evidence for the prevention and treatment of heart failure related to certain established chemotherapeutic drugs, whereas there is lack of trials for specific cardioprotective strategies to reduce cardiotoxicity of newer targeted cancer therapies.RECENT FINDINGSRecent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD. However, this is largely based on data extrapolated from the general heart failure population (including patients without cancers) and is not based on strong evidence. There is now emerging evidence for the prevention and treatment of heart failure related to certain established chemotherapeutic drugs, whereas there is lack of trials for specific cardioprotective strategies to reduce cardiotoxicity of newer targeted cancer therapies.In this article, we discuss the most recent literature for the management of asymptomatic left ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use of goal-directed medical therapies as well as discuss the role for advanced heart failure treatment in this population.SUMMARYIn this article, we discuss the most recent literature for the management of asymptomatic left ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use of goal-directed medical therapies as well as discuss the role for advanced heart failure treatment in this population. The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival. Recent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD. However, this is largely based on data extrapolated from the general heart failure population (including patients without cancers) and is not based on strong evidence. There is now emerging evidence for the prevention and treatment of heart failure related to certain established chemotherapeutic drugs, whereas there is lack of trials for specific cardioprotective strategies to reduce cardiotoxicity of newer targeted cancer therapies. In this article, we discuss the most recent literature for the management of asymptomatic left ventricular dysfunction and heart failure related to chemotherapy, from prevention to the use of goal-directed medical therapies as well as discuss the role for advanced heart failure treatment in this population. |
| Author | Taylor, Marian H Cai, Amanda W Ramu, Bhavadharini |
| Author_xml | – sequence: 1 givenname: Amanda W surname: Cai fullname: Cai, Amanda W organization: Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA – sequence: 2 givenname: Marian H surname: Taylor fullname: Taylor, Marian H – sequence: 3 givenname: Bhavadharini surname: Ramu fullname: Ramu, Bhavadharini |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30747732$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNz0tLxDAUBeAgI85D_4FIl2465p12KUUdYWA247rE5JZWmqYm6aL_3hFHmLs5Z_Fx4K7RYvADIHRP8JbgUj3tqsMWX54k_AqtiGAkV7jAi4u-ROsYv06GlqW8QUuGFVeK0RVixwA6ORhS5pvMtOB8aiHocc51jN50OoHNjA628272o07tfIuuG91HuDvnBn28vhyrXb4_vL1Xz_vcMCF5boy0BDDhVumiYcJS4JwxwhkoVZSEUJBCYU0LKRtsG3byAFZZLTgYwekGPf7tjsF_TxBT7bpooO_1AH6KNaVYlZyS4pc-nOn06cDWY-icDnP9_yj9AZyoVwM |
| CitedBy_id | crossref_primary_10_3390_jcm10163731 crossref_primary_10_1002_ehf2_14045 crossref_primary_10_3390_antiox9121292 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/HCO.0000000000000614 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1531-7080 |
| ExternalDocumentID | 30747732 |
| Genre | Journal Article Review |
| GroupedDBID | --- .-D .GJ .Z2 01Q 0R~ 4Q1 4Q2 4Q3 53G 5GY 5VS 6PF 8L- AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AAWTL AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABVCZ ABXVJ ABZAD ABZZY ACDDN ACEWG ACGFO ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFMFG AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 BYPQX C45 CAG CGR COF CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C LEELO N9A NPM N~M O9- OAG OAH OCUKA ODA OL1 OLC OLG OLV OLZ OPUJH ORVUJ OUVQU OVD OVDKG OVDNE OVKID OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XO3 XXN XYM YFH ZFV ZZMQN 7X8 ABPXF ACBKD ADKSD |
| ID | FETCH-LOGICAL-c3564-cc6d1e014d7a8f35d2e4433143e7789112e6570a2866f0df3c6deed7da54ec542 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000472722500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1531-7080 |
| IngestDate | Sun Nov 09 13:55:31 EST 2025 Thu Apr 03 07:05:04 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3564-cc6d1e014d7a8f35d2e4433143e7789112e6570a2866f0df3c6deed7da54ec542 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 30747732 |
| PQID | 2207942184 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2207942184 pubmed_primary_30747732 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-May |
| PublicationDateYYYYMMDD | 2019-05-01 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-May |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Current opinion in cardiology |
| PublicationTitleAlternate | Curr Opin Cardiol |
| PublicationYear | 2019 |
| SSID | ssj0002996 |
| Score | 2.232307 |
| SecondaryResourceType | review_article |
| Snippet | The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 296 |
| SubjectTerms | Antineoplastic Agents - adverse effects Cardiomyopathies - chemically induced Cardiomyopathies - therapy Cardiotoxicity - therapy Heart Diseases - chemically induced Heart Diseases - therapy Humans Neoplasms - drug therapy |
| Title | Treatment of chemotherapy-associated cardiomyopathy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30747732 https://www.proquest.com/docview/2207942184 |
| Volume | 34 |
| WOSCitedRecordID | wos000472722500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLaAIcSF92O8VCSu0dokTZoTQhPTDmzsMNBuU5akEoe1gwHS_j1Om2onJCR66KmpKtu1v8T2Z4A7hWFuxpwgiaaacGo00U5RYk1KhXTU6ipj-vokh8NsMlGjcOC2DGWVjU-sHLUtjT8j71Aao-n4Dcn94p34qVE-uxpGaGxCiyGU8VYtJ2u2cHS1ouZLTYhEaNS0zinZ6Xefa-rC5hK-j-c3kFkFm97-fz_zAPYCzIwears4hA1XHMHOICTSj4GNmwLzqMwjVNw8dGKtiA4KczYyVbHqfFX6ucWrE3jpPY67fRLmJxDDUsGJMcImDvdAVuosZ6mljvsGKc6clBl6Oep84YummRB5bHOGz2PIlFan3JmU01PYKsrCnUNk8TVxbGc8MTOex1KbXCmjTKrTxCKma8NtI44p2qdPOujClV_L6VogbTirZTpd1EQaU-bZ-yWjF39YfQm7iFVUXWt4Ba0c_053Ddvm-_Nt-XFTKR7vw9HgB7xhtpc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+chemotherapy-associated+cardiomyopathy&rft.jtitle=Current+opinion+in+cardiology&rft.au=Cai%2C+Amanda+W&rft.au=Taylor%2C+Marian+H&rft.au=Ramu%2C+Bhavadharini&rft.date=2019-05-01&rft.eissn=1531-7080&rft.volume=34&rft.issue=3&rft.spage=296&rft_id=info:doi/10.1097%2FHCO.0000000000000614&rft_id=info%3Apmid%2F30747732&rft_id=info%3Apmid%2F30747732&rft.externalDocID=30747732 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1531-7080&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1531-7080&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1531-7080&client=summon |